Related Experiment Video
Updated: Dec 20, 2025
SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
Published on: June 28, 2019
Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis
Yoshihiro Hayakawa1, Stefania Rovero, Guido Forni
1Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, Melbourne 8006, Australia.
Abstract:
Recent studies have revealed significant efficacy of the marine sponge glycolipid, alpha-galactosylceramide (alpha-GalCer), in treatment of experimental metastatic cancers, infections, and autoimmune diseases. However, the capacity of alpha-GalCer to prevent tumor development had never, to our knowledge, been evaluated in mouse models of chemical- and oncogene-dependent carcinogenesis. In this study, we demonstrate that long-term administration of soluble alpha-GalCer, spanning the time of tumor initiation, inhibits primary tumor formation in three different models: methylcholanthrene-induced sarcomas, mammary carcinomas in Her-2/neu transgenic mice, and spontaneous sarcomas in p53-/- mice. Weekly treatment of mice with alpha-GalCer maintained lymphoid tissue natural killer cell and T cell activation and elevated serum IFN-gamma and IL-4 concentrations. Consistent with the antimetastatic activity of alpha-GalCer, prevention of methylcholanthrene-induced sarcoma was IFN-gammaand tumor necrosis factor-related apoptosis-inducing ligand dependent, but not perforin-dependent. Taken together, our results demonstrate that NK1.1+alphabetaTCR+ cell-based immune therapy can inhibit primary tumorigenesis.
Insights
Marine sponge glycolipid, alpha-galactosylceramide (alpha-GalCer), prevents primary tumor formation in mouse models. This immune therapy activates natural killer and T cells, showing potential for cancer prevention.
Area of Science:
- Immunology
- Oncology
- Marine Biotechnology
Background:
- Marine sponge glycolipid alpha-galactosylceramide (alpha-GalCer) shows efficacy in treating cancers, infections, and autoimmune diseases.
- The potential of alpha-GalCer in preventing primary tumor development in chemical- and oncogene-dependent carcinogenesis models was previously unevaluated.
Purpose of the Study:
- To evaluate the capacity of alpha-GalCer to prevent primary tumor development in mouse models of chemical- and oncogene-dependent carcinogenesis.
- To investigate the immune mechanisms underlying alpha-GalCer's tumor-preventive effects.
Main Methods:
- Long-term administration of soluble alpha-GalCer during tumor initiation in mouse models.
- Assessment of primary tumor formation in methylcholanthrene-induced sarcomas, Her-2/neu transgenic mice (mammary carcinomas), and p53-/- mice (spontaneous sarcomas).
- Monitoring of natural killer (NK) cell and T cell activation, serum IFN-gamma and IL-4 levels, and dependence on IFN-gamma, TNF-related apoptosis-inducing ligand (TRAIL), and perforin for tumor prevention.
Main Results:
- Long-term alpha-GalCer administration inhibited primary tumor formation across three distinct models.
- Weekly alpha-GalCer treatment maintained NK and T cell activation, elevating serum IFN-gamma and IL-4.
- Tumor prevention was dependent on IFN-gamma and TRAIL, but not perforin, consistent with alpha-GalCer's antimetastatic activity.
Conclusions:
- Alpha-galactosylceramide demonstrates significant potential in preventing primary tumor development.
- NK1.1+alphabetaTCR+ cell-based immune therapy, mediated by alpha-GalCer, can inhibit primary tumorigenesis.
- The findings support the exploration of alpha-GalCer as a prophylactic agent against chemically and oncogenically induced cancers.
